Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations

More>>

Smith, W.J., Drew, R.H. and Perfect, J.R. (2009) Posaconazole’s impact on prophylaxis and treatment of invasive fungal infections: an update. Expert Review of Anti- Infective Therapy, 7(2), 165-181.

has been cited by the following article:

  • TITLE: Treatment of chronic vulvovaginal candidiasis with posaconazole and ciclopiroxolamine

    AUTHORS: Hans-Jürgen Tietz

    KEYWORDS: Chronic Recurrent Vulvovaginal Candidiasis; VVC; Candida Glabrata; Posaconazole

    JOURNAL NAME: Health, Vol.2 No.6, June 28, 2010

    ABSTRACT: Therapy of chronic recurrent vulvovaginal can- didiasis (VVC) caused by Candida glabrata is still rare in comparison to C. albicans infection, but therapy remains more difficult. Combination therapy with topical antifungals may improve therapy outcome, but still standard agents as fluconazole or itraconazole often fail. Posaconazole is a new systemic triazole with a wide antifungal spectrum including rare Candida species. Up to now, no clinical trials with posa- conazole in chronic recurrent VVC have been undertaken. Here, first results of the application of a new therapy regimen consisting of oral posaconazole in combination with topical ciclopiroxolamine are presented. 15 patients with chronic recurrent VVC caused by C. glabrata have been treated. 14 of these patients experienced successful therapy, clinical and mycological cure 30 days after begin of therapy has been observed. Long-term results are promising, as in 4 patients clinical and mycologic cure persists for more than 1 year up to now.